---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-006267"
form_type: "8-K"
ticker: "APRE"
cik: "0001781983"
company_name: "Aprea Therapeutics, Inc."
filed_at: "2026-01-23T23:59:59+00:00"
generated_at: "2026-05-16T08:28:00.441539+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aprea Therapeutics receives Nasdaq bid price deficiency notice; stock at risk of delisting

## Summary
- Closing bid below $1.00 for 30 consecutive business days triggered Nasdaq deficiency letter.
- Company has 180 calendar days (until July 22, 2026) to regain compliance via $1.00 close for 10 consecutive days.
- If not cured by July 22, Aprea may qualify for a second 180-day period if it meets other listing standards.
- Company may consider a reverse stock split to cure the deficiency but no assurance of compliance.
- Stock continues trading on Nasdaq Capital Market under symbol APRE with no immediate delisting effect.

## SEC filing metadata
- accession: 0001104659-26-006267
- form_type: 8-K
- ticker: APRE
- cik: 0001781983
- company_name: Aprea Therapeutics, Inc.
- filed_at: 2026-01-23T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781983/000110465926006267/0001104659-26-006267-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781983/000110465926006267/tm263963d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-006267
- JSON: https://secwatch.observer/filing/0001104659-26-006267.json
- Plain text: https://secwatch.observer/filing/0001104659-26-006267.txt

## Source-grounded claims
- claim_id: f2976c751194bfc933eaf1f19f7597cffb29b0d0
  claim: Aprea Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
  evidence_excerpt: January 23, 2026, Aprea Therapeutics, Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Nasdaq deficiency letter has no immediate effect on the listing of the Company’s common stock
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781983/000110465926006267/0001104659-26-006267-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.